131 related articles for article (PubMed ID: 33631410)
1. Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5Rα in a real-world setting.
Bavaro N; Gakpo D; Mittal A; Bensko JC; Laidlaw TM; Buchheit KM
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2910-2912.e1. PubMed ID: 33631410
[No Abstract] [Full Text] [Related]
2. IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.
Buchheit KM; Dwyer DF; Ordovas-Montanes J; Katz HR; Lewis E; Vukovic M; Lai J; Bankova LG; Bhattacharyya N; Shalek AK; Barrett NA; Boyce JA; Laidlaw TM
J Allergy Clin Immunol; 2020 Jun; 145(6):1574-1584. PubMed ID: 32199912
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab as Add-on Therapy for Chronic Rhinosinusitis With Nasal Polyposis in Aspirin Exacerbated Respiratory Disease.
Mustafa SS; Vadamalai K; Scott B; Ramsey A
Am J Rhinol Allergy; 2021 May; 35(3):399-407. PubMed ID: 32967430
[TBL] [Abstract][Full Text] [Related]
4. Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP.
Minagawa S; Araya J; Watanabe N; Fujimoto S; Watanabe J; Hara H; Numata T; Kuwano K; Matsuwaki Y
BMC Pulm Med; 2022 Jun; 22(1):258. PubMed ID: 35764984
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease.
Yong M; Wu YQ; Howlett J; Ballreich J; Walgama E; Thamboo A
Int Forum Allergy Rhinol; 2021 Dec; 11(12):1626-1636. PubMed ID: 34309219
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease.
Mustafa SS; Vadamalai K
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):738-739. PubMed ID: 33746062
[No Abstract] [Full Text] [Related]
8. Efficacy of various dosing frequencies of dupilumab in patients with aspirin-exacerbated respiratory disease.
Brown AN; Laidlaw TM; Buchheit KM; Bensko JC; Corcoran RC; Bailey LB
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1647-1648. PubMed ID: 38484871
[No Abstract] [Full Text] [Related]
9. Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps.
Hoy SM
Drugs; 2020 May; 80(7):711-717. PubMed ID: 32240527
[TBL] [Abstract][Full Text] [Related]
10. Aspirin-exacerbated respiratory disease and current treatment modalities.
Sakalar EG; Muluk NB; Kar M; Cingi C
Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1291-1300. PubMed ID: 27538737
[TBL] [Abstract][Full Text] [Related]
11. Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps.
Kilty SJ; Lasso A
J Otolaryngol Head Neck Surg; 2022 Apr; 51(1):17. PubMed ID: 35468866
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis.
Maspero JF; Katelaris CH; Busse WW; Castro M; Corren J; Chipps BE; Peters AT; Pavord ID; Ford LB; Sher L; Rabe KF; Rice MS; Rowe P; Lu Y; Harel S; Jagerschmidt A; Khan AH; Kamat S; Pirozzi G; Amin N; Ruddy M; Graham NMH; Mannent LP; Teper A
J Allergy Clin Immunol Pract; 2020 Feb; 8(2):527-539.e9. PubMed ID: 31351189
[TBL] [Abstract][Full Text] [Related]
13. Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies.
Geng B; Bachert C; Busse WW; Gevaert P; Lee SE; Niederman MS; Chen Z; Lu X; Khokhar FA; Kapoor U; Pandit-Abid N; Jacob-Nara JA; Rowe PJ; Deniz Y; Ortiz B
J Allergy Clin Immunol Pract; 2022 Mar; 10(3):732-741. PubMed ID: 34954123
[TBL] [Abstract][Full Text] [Related]
14. Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab.
Kariyawasam HH
Expert Rev Clin Immunol; 2020 Dec; 16(12):1115-1125. PubMed ID: 33148074
[No Abstract] [Full Text] [Related]
15. Decreased nasal polyp eosinophils but increased mast cells in a patient with aspirin-exacerbated respiratory disease treated with reslizumab.
Staudacher AG; Peters AT; Carter RG; Welch KC; Stevens WW
Ann Allergy Asthma Immunol; 2020 Oct; 125(4):490-493.e2. PubMed ID: 32629015
[No Abstract] [Full Text] [Related]
16. Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy.
Mümmler C; Munker D; Barnikel M; Veit T; Kayser MZ; Welte T; Behr J; Kneidinger N; Suhling H; Milger K
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1177-1185.e4. PubMed ID: 32980583
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.
Jonstam K; Swanson BN; Mannent LP; Cardell LO; Tian N; Wang Y; Zhang D; Fan C; Holtappels G; Hamilton JD; Grabher A; Graham NMH; Pirozzi G; Bachert C
Allergy; 2019 Apr; 74(4):743-752. PubMed ID: 30488542
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab in the treatment of chronic rhinosinusitis with nasal polyposis.
Boyle JV; Lam K; Han JK
Immunotherapy; 2020 Feb; 12(2):111-121. PubMed ID: 32075470
[TBL] [Abstract][Full Text] [Related]
19. Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma.
Drick N; Milger K; Seeliger B; Fuge J; Korn S; Buhl R; Schuhmann M; Herth F; Kendziora B; Behr J; Kneidinger N; Bergmann KC; Taube C; Welte T; Suhling H
J Asthma Allergy; 2020; 13():605-614. PubMed ID: 33204117
[TBL] [Abstract][Full Text] [Related]
20. Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis.
Bachert C; Zhang L; Gevaert P
J Allergy Clin Immunol; 2015 Dec; 136(6):1431-1440. PubMed ID: 26654192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
